Candel Therapeutics’ CAN-3110 Clinical Data Selected for Oral Presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
NEEDHAM, Mass.– Candel Therapeutics, Inc., a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced that an abstract has been accepted for oral presentation at the upcoming 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held virtually from June 4-8, 2021. The abstract will include clinical data from Candel’s Phase 1 trial evaluating CAN-3110 in patients with recurrent high-grade glioma which will be presented by lead investigator E. Antonio Chiocca, M.D., Ph.D., Neurosurgeon-In-Chief and Chairman, Department of Neurosurgery, Brigham and Women’s Hospital and Professor, Harvard Medical School.
Details of the presentation are as follows:
Abstract Title: First-in-human CAN-3110 (ICP-34.5 expressing HSV-1 oncolytic virus) in patients with recurrent high-grade glioma
Presenter: Dr. E. Antonio Chiocca
Session Date and Time: The presentation will be available to attendees beginning June 4, 2021 at 9 AM EDT/ 6 AM PDT
Abstract Link: https://meetinglibrary.asco.org/session/13562
Session Title: CNS Targeting: From Delivery to Biomarker Assessment
Abstract Number: 2009
About CAN-3110
CAN-3110 is an HSV replication-competent oncolytic virus engineered to enhance selective killing of malignant cells while sparing healthy normal neighboring cells.
Candel is evaluating the effects of treatment with CAN-3110 for recurrent glioblastoma. For more information on this clinical study, please visit https://www.clinicaltrials.gov/ct2/show/NCT03152318?term=candel&draw=3
About Candel Therapeutics
Candel is a late clinical stage biopharmaceutical company focused on helping patients fight cancer with oncolytic viral immunotherapies. Our engineered viruses are designed to induce immunogenic cell death through direct viral-mediated cytotoxicity in cancer cells, thus releasing tumor neo-antigens and creating a pro-inflammatory microenvironment at the site of injection. Our approach combines an in-depth knowledge of viral immunotherapy with extensive clinical experience across a wide range of indications. Based on the broad range of data that we have generated from our preclinical models and clinical trials using our approach, we have observed what we believe to be a systemic immune response against locally injected tumors and their distant metastases. To learn more, visit www.candeltx.com.
Media Contact
Heidi Chokeir, Ph.D.
Managing Director
Canale Communications
heidi.chokeir@canalecomm.com
619-203-5391